[1]CHEN WQ,ZHENG RS,BAADE PD,et al.Cancer statistics in China,2015[J].Ca Cancer J Clin,2016,66(2):115-132.
[2]HERBST RS,HEYMACH JV,LIPPMAN SM.Lung cancer[J].New England Journal of Medicine,2008,359(13):1367-1380.
[3]RUSSO A,FRANCHINAT,RICCIARD G,et al.Heterogeneous responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with uncommon EGFR mutations:New insights and future perspectives in this complex clinical scenario[J].Int J Mol Sci,2019,20(6):1431.
[4]MORGILLO F,DELLA CC,FASANO M,et al.Mechanisms of resistance to EGFR-targeted drugs:lung cancer[J].Esmo Open,2016,1(3):e000060.
[5]KEAM B,KIM DW,JIN HP,et al.Rare and complex mutations of epidermal growth factor receptor,and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer[J].International Journal of Clinical Oncology,2014,19(4):594-600.
[6]LOHINAI Z,HODA MA,FABIAN K,et al.Distinct epidemiology and clinical consequence of classic versus rare EGFR mutations in lung adenocarcinoma[J].Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer,2015,10(5):738-746.
[7]BAEK JH,SUN J,MIM YJ,et al.Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non-small cell lung cancer except both exon 19 deletion and exon 21 L858R:A retrospective analysis in Korea[J].Lung Cancer,2015,87(2):148-154.
[8]SALEH K,KHALIFESALEH N,HADDAD EE,et al.Negative predictive biomarkers of checkpoint inhibitors in hyper-progressive tumors[J].Biomarkers in Medicine,2017,11(10):819-821.
[9]马薇,罗殿中,陈源,等.PD-L1和PD-1在非小细胞肺癌中的表达及其临床意义[J].实用医学杂志,2011,27(9):1551-1554.
MA W,LUO DZ,CHEN Y,et al.Expression and clinical significance of PD-L1 and PD-1 in non-small cell lung cancer[J].The Journal of Practical Medicine,211,27(9):1551-1554.
[10]AVALLONE G,ROCCABIANCA P,CRIPA L,et al.Histological classification and immunohistochemical evaluation of MDM2 and CDK4 expression in canine liposarcoma[J].Veterinary Pathology,2016,53(4):773-780.
[11]FREGA S,LORENZI M,FASSAN M,et al.Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations[J].Oncotarget,2017,8(20):32626-32638.
[12]KEAM B,KIM DW,PARK JH,et al.Rare and complex mutations of epidermal growth factor receptor,and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer[J].International Journal of Clinical Oncology,2014,19(4):594-600.
[13]MARTIN J,LEHMANN A,KLAUSCHEN F,et al.Clinical impact of rare and compound mutations of epidermal growth factor receptor in patients with non-small-cell lung cancer[J].Clin Lung Cancer,2019,20(5):350-362.
[14]OZYUREK BA,OZDEMIREL TS,OZDEN SB,et al.Prognostic value of the neutrophil to lymphocyte ratio (NLR) in lung cancer cases[J].Asian Pacific Journal of Cancer Prevention Apjcp,2017,18(5):1417-1421.
[15]CHEN K,YU X,WANG H,et al.Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients[J].Cancer Chemotherapy & Pharmacology,2017,80(6):1179-1187.
[16]FREGA S,LORENZI M,FASSAN M,et al.Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations[J].Oncotarget,2017,8(20):32626-32638.
[17]KOBAYASHI Y,MITSUDOMI T.Not all epidermal growth factor receptor mutations in lung cancer are created equal:Perspectives for individualized treatment strategy[J].Cancer Science,2016,107(9):1179-1186.
[18]CHANTHARASAMEE J,POUNGVARIN N,DANCHAIVIJITR P,et al.Clinical outcome of treatment of metastatic non-small cell lung cancer in patients harboring uncommon EGFR mutation[J].BMC Cancer,2019,19(1):701.
[19]AL-SHIBILI IK,DONNEM T,AL-SAAD S,et al.The prognostic value of intraepithelial and stromal T cells,mast cells and plasma cells in non-small cell lung carcinoma[J].Virchows Archiv,2009,455:85.